NEUROTOXICITY EFFECT IN CANCER REGIMENT CARBOPLATIN-PACLITAXEL
DOI:
https://doi.org/10.22159/ajpcr.2021.v14i10.42929Keywords:
ADRs, Neuropathy, Motoric, Arthalgia, Muscle, Carboplatin, Paclitaxel, CTCAE, CyclesAbstract
Objective: Side effects due to chemotherapy were frequently reported and some of them require immediate treatment. Cervical cancer, breast cancer, and ovarian cancer are types of cancer that are often found in Dr. Moewardi Surakarta Hospital and 45% of the three types of cancer used the chemotherapy regimen of carboplatin-paclitaxel. Carboplatin-paclitaxel was chosen because it is a regimen that has fewer side effects.
Methods: This study aims to identify the type of adverse drug reactions (ADRs) neurotoxicity, percentage, and severity, as well as to determine the risk factors for the occurrence of ADRs such as age, gender, type of cancer, number of cycles, length of stay, and types of comorbidities in cancer patients using carboplatin-paclitaxel therapy regimen in RSUD Dr. Moewardi Surakarta for the period September to December 2019. This study was an observational study with a cross-sectional design through prospective data searches. The inclusion criteria in this study were adult cancer patients on carboplatin-paclitaxel therapy who were willing to be research subjects.
Results: The incidences of ADRs in patients using the carboplatin-paclitaxel therapy regimen in this study were sensory peripheral neuropathy (77.69%); motor peripheral neuropathy (3.31%); joint pain (53.72%); and muscle weakness (37.19%) The instrument to measure the severity in this study used common terminology criteria for adverse events with the results of ADRs with grade 1 (35.08%), grade 2 (61.02), grade 3 (2.88%), and at grades 4 and 5 (0%). Risk factors for gender, age, length of stay, type of cancer, number of cycles, and comorbidities did not affect the incidence of neurotoxicity in cancer patients with the carboplatin-paclitaxel therapy regimen.
Downloads
References
Canadian association of pharmacy in oncology. Oncol Basics Oncol Pract Essent 2005;20:52-8.
World Health Organization. Latest Global Cancer Data. Geneva: World Health Organization; 2018.
Singh S, Dhasmana DC, Singh PK. Pattern of adverse drug reactions to anticancer drugs: A quantitative and qualitative analysis. Indian J Med Paediatr Oncol 2017;38:140-5.
BC Cancer Agency. CRBPPACL (Carboplatin-Paclitaxel) Regimen. Canada: BC Cancer Agency; 2019.
Akin JM, Waddell JA, Solimando DA. Paclitaxel and carboplatin (TC) regimen for ovarian cancer. Hosp Pharm 2014;49:425-31.
Aberg L, Lacy C, Goldman M, Lance L. Drug Information Handbook. 17th ed. United States: Lexycomp; 2009.
Indrayathi PA, Noviyani R, Niruri R, Budiana IN, Tunas K. Difference in blood function toxicity between stadium IIB-IIIB squamous cell cervical cancer patients with paclitaxel cisplatin and paclitaxel carboplatin chemotherapy at Sanglah hospital, Denpasar. Asian J Pharm Clin Res 2018;11:224-7.
Thapaliya K, Shrestha A, Prajapati S, Subedi R, Giri S. Study of pattern of adverse drug reaction due to cancer chemotherapy and their management in hospitalized patient in BP Koirala memorial cancer hospital. J Chitwan Med Coll 2014;4:24-8.
Schatz BS, Pharm D, Weber RJ, Pharm D. Adverse Drug Reactions. United States: American Collage of Clinical Pharmacy; 2015.
Fountzilas BG, Bafaloukos D, Aravantinos G. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Cancer Network 1998;12:45-8.
NCCN. Cervical Cancer Treatment Regimens. Cancer Therapy Advisor. United States: NCCN; 2019. p. 1-8.
Fotopoulou C. Limitations to the use of carboplatin-based therapy in advanced ovarian cancer. Eur J Cancer Suppl 2014;12:13-6.
Kolek V. Advantages and disadvantages of Cisplatin or carboplatin in adjuvant chemotherapy of NSCLC. Transl Lung Cancer Res 2014;3:7.
Kumar S, Badruddeen B, Singh SP, Khan MI. A prospective study of adverse drug reactions due to platinum analogs-chemotherapy in a tertiary care hospital. Asian J Pharm Clin Res 2018;11:215-8.
Kim JW, Lee Y, Hwang IG, Song HS, Koh SJ, Ko YH, et al. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean cancer study group (KCSG) multicentre prospective study. Br J Cancer 2018;118:1169-75.
Staff NP, Grisold A, Grisold W, Windebank AJ, Clinic M. Chemotherapy induced peripheral neuropathy-current review. Ann Neurol 2018;81:772-81.
Saini VK, Sewal RK, Ahmad Y, Medhi B. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J Pharm Sci 2015;77:687- 93.
Wang F, Du X, Li X, Liu N, Yu H, Sheng X. Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer. Medicine 2016;95:1-7.
Shrestha S, Shakya R, Shrestha S, Shakya S. Adverse drug reaction due to cancer chemotherapy and its financial burden in different hospitals of Nepal. Int J Pharmacovig 2017;2:1-7.
Zhang M, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: Retrospective cohort study. BMJ Open 2009;338:1-21.
Sneha SG, Simhadri K, Subeesh VK, Sneha SV. Predictors of adverse drug reactions in geriatric patients: An exploratory study among cancer patients. South Asian J Cancer 2019;8:130-3.
Published
How to Cite
Issue
Section
Copyright (c) 2021 ANNISA DIYAN MEITASARI, EM SUTRISNA, ZAKKY CHOLISOH
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
